Ameloblastoma is a neoplasm that is classified as a benign odontogenous tumor in the mandible. Ameloblastoma can turn into a malignancy. The incidence of benign ameloblastoma about 0.5 per 1,000,000 population annually. While, the incidence of malignant Ameloblastoma about 1.79 per 10,000,000 population annually. As much as 80-93% ameloblastoma occurs in the posterior mandibular part. In eastern Indonesia, studies show that from 2011-2016 there were 84 people with ameloblastoma. Handling of ameloblastoma will leave a defect on the rest of the surrounding tissue. Therefore, new therapy is needed to reduce defect in the former of ameloblastoma. The purpose of this paper is to know the potential combination of Periodontal Ligament-Derived Stem Cells (PLDSCs) with acemannan on chitosan-composites scaffold for regeneration of ameloblastoma defects. Ameloblastoma is an odontogenic benign tumor derived from an unerupted tooth. Ameloblastoma in the mandible can develop very large and cause facial asymmetry, changes in the position of the tooth and pathological fracture. In ameloblastoma treatment performed is the action of tumor resection. These resections produce defects in surrounding tissues, especially in ameloblastoma malignant. Research shows that PLDSCs can correct defects bone by promoting the formation of mineralized tissue equivalent to Bone Marrow Stem Cells. Acemannan serves as an immunomodulator that can increase the body's defense specifically. Chitosan-composite scaffold as a bone regeneration medium that is widely used to regenerate bones because, it has a natural intrinsic antibacterial, biocompatibility and good biodegradability and high mechanical strength. The combination of PLDSCs with acemannan on chitosan-composites scaffold has the potential to regenerate the ameloblastoma defect.
- Ameloblastoma defect
- Chitosan-composites scaffold